CHEVROPIS: Clinical and Hemodynamic Evaluation After Venous Recanalization of Post-thrombotic Iliofemoral Syndromes

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Completed
CT.gov ID
NCT05954663
Collaborator
(none)
24
1
15.8
1.5

Study Details

Study Description

Brief Summary

Post-thrombotic syndrome (PTS) is the most common chronic complication of deep vein thrombosis (DVT). The endovascular recanalization and stenting technique has become the gold standard treatment for medically resistant and disabling PTS.

Stent thrombosis is a significant complication of this procedure; the risk factors for thrombosis are poorly understood.

Monitoring the patency of the stent is a key component in maintaining clinical success.

Doppler ultrasound is the first-line diagnostic tool for monitoring patients with venous stents, and has the potential to allow accurate assessment of venous stent obstruction.

Absence of validated morphological and hemodynamic echodoppler criteria for the follow-up of these stents.

• Main objective: Clinical and hemodynamic results of venous recanalisations by stenting in the chronic phase

• Secondary objective (s):

  • External validation of hemodynamic criteria proposed in the literature to detect venous stent obstruction

  • Risk factors for venous stent restenosis

Condition or Disease Intervention/Treatment Phase
  • Other: Basic demographic information

Study Design

Study Type:
Observational
Actual Enrollment :
24 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Clinical and Hemodynamic Evaluation After Venous Recanalization of Post-thrombotic Iliofemoral Syndromes
Actual Study Start Date :
Nov 1, 2020
Actual Primary Completion Date :
Feb 1, 2022
Actual Study Completion Date :
Feb 26, 2022

Arms and Interventions

Arm Intervention/Treatment
Patients who underwent venous recanalization by angioplasty-stenting

Patients who underwent venous recanalization by angioplasty-stenting for post-thrombotic iliofemoral syndromes from June 2014 to June 2021.

Other: Basic demographic information
Basic demographic information: age, sex, weight, height, BMI. Comorbidities: history of major bleeding, cardiovascular comorbidities, diabetes mellitus, renal failure, smoking, hormone therapy Anticoagulant and antiplatelet therapy (molecule, duration and indication, before and after intervention) Procedure data: number and type of stents implanted, diameters and lengths, name of stented venous segments Postoperative complications: bleeding complications, pelvic pain, early thrombosis, early pulmonary embolism Clinical examination carried out 1 month after the operation and more than 6 months after the operation Data from the control ultrasound performed 1 month after the operation and more than 6 months after the operation

Outcome Measures

Primary Outcome Measures

  1. Clinical improvement [6 first month post intervention]

    Villalta score Score ≤ 4: No TPS. Score between 5 and 14: mild TPS. Score between 10-14: moderate TPS. Score ≥ 15 or ulcer present: severe TPS.

  2. Stent patency [6 first month post intervention]

    Analyze of venous patency of each venous segment Maximum peak flow velocity (in centimetres per second) at each venous segment Location of the implanted stents Cranial and caudal extremity Total length Diameter

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 67 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Disabling post-thrombotic syndrome (venous claudication) after at least 6 months of proximal deep vein thrombosis.
Exclusion Criteria:
  • Inability to consent

  • Age <18 years old

  • Life expectancy <3 months

  • Incomplete medical records

  • Lost in follow up

Contacts and Locations

Locations

Site City State Country Postal Code
1 Groupement Hospitalier Edouard Herriot Lyon France 69437

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT05954663
Other Study ID Numbers:
  • 69HCL22_1131
First Posted:
Jul 20, 2023
Last Update Posted:
Jul 21, 2023
Last Verified:
Jul 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospices Civils de Lyon
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2023